Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy
Academic Article
Publication Date:
2020
abstract:
This is a commentary on Agnes Mattsson. et al., Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Iris type:
14.a.1 Articolo su rivista
Keywords:
chronic lymphocytic leukaemia (CLL, fludarabine, cyclophosphamide and rituximab (FCR
List of contributors:
Mondello, Patrizia; Zelenetz, Andrew D.
Published in: